What is Oramed Pharmaceuticals, Inc Annual Revenue?

Oramed Pharmaceuticals, Inc Annual Revenue fell 33.7%, in the last year to $1.34 M. Its sector's average revenue growth for the last fiscal year was 7.46%.

What is Oramed Pharmaceuticals, Inc Annual Net Profit?

Oramed Pharmaceuticals, Inc Annual Net Profit rose 133.78% in the last year to $5.52 M. Its sector's average net profit growth for the last fiscal year was -32.43%.

What is Oramed Pharmaceuticals, Inc Price to Earning Ratio?

Oramed Pharmaceuticals, Inc Price to Earning Ratio is 21.04, higher than its sector PE ratio of 4.23.

What is Oramed Pharmaceuticals, Inc Stock Price?

Oramed Pharmaceuticals, Inc Stock Price fell 19.93% and underperformed its sector by 29% in the past year.

What is Oramed Pharmaceuticals, Inc Quarterly Net profit?

Oramed Pharmaceuticals, Inc Quarterly Net profit fell 508.91% YoY to $19.62 M. Its sector's average net profit growth YoY for the quarter was -47.3%.

What is Oramed Pharmaceuticals, Inc Debt to Equity Ratio?

Oramed Pharmaceuticals, Inc Debt to Equity Ratio of 0.32 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Oramed Pharmaceuticals, Inc Return on Equity(ROE)?

Oramed Pharmaceuticals, Inc Return on Equity(ROE) for the last financial year was 3.5%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Oramed Pharmaceuticals, Inc Mutual Fund Holding?

Oramed Pharmaceuticals, Inc Mutual Fund Holding increased by 0.3% in the last quarter to 1.28.

What is Oramed Pharmaceuticals, Inc Promoter Share Holding?

Oramed Pharmaceuticals, Inc Promoter Share Holding increased by 10.34% in the most recent quarter to 119.63%.

What is Oramed Pharmaceuticals, Inc Interest Coverage Ratio?

Oramed Pharmaceuticals, Inc Interest Coverage Ratio is 3.5, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

What is Oramed Pharmaceuticals, Inc Institutional Holding?

Oramed Pharmaceuticals, Inc Institutional Holding increased by 1.76% in the last quarter to 19.18.

How is the Oramed Pharmaceuticals, Inc today?

The Oramed Pharmaceuticals, Inc today is trading in the down by -1.69% at 2.33.

How has Oramed Pharmaceuticals, Inc performed historically?

The Oramed Pharmaceuticals, Inc is currently trading down -1.69% on an intraday basis in the past week the index fell -2.51%. The index has been down -1.69% in the past quarter and fell -19.93% in the past year. You can view this in the overview section.

Oramed Pharmaceuticals, Inc XNAS: ORMP

Oramed Pharmaceuticals, Inc Live Share Price Today, Share Analysis and Chart

Name: Oramed Pharmaceuticals, Inc: Is Infosys Ltd. worth buying?
Item: Oramed Pharmaceuticals, Inc
Rating: 2.00075
Author: Trendlyne DVM scores

Download real time

2.33 -0.04 (-1.69%)

25.80% Fall from 52W High

16,814 XNAS Volume

XNAS 21 Mar, 2025 5:30 PM (EDT)

Board Meeting

The next board meeting for Oramed Pharmaceuticals, Inc is on 27 Mar 2025 for the purpose of Oramed Pharmaceuticals Inc Annual Report for 2024 See details

Oramed Pharmaceuticals, Inc Key Metrics

My Metrics

Select

Market Capitalization Below industry Median Unavailable in chosen country	93.9
PE TTM High in industry Unavailable in chosen country	21
PEG TTM Below industry Median Unavailable in chosen country	0.2
Price to Book Below industry Median Unavailable in chosen country	0.6
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	19.2
Operating Revenue growth TTM % Negative Operating Revenue growth TTM % Unavailable in chosen country	-100
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-508.9
Net Profit TTM Growth % High in industry Unavailable in chosen country	127.3
Piotroski Score High in industry Unavailable in chosen country	4
Rel Perf vs Sector quarter% Unavailable in chosen country	-10.3
ROE Annual % High in industry Unavailable in chosen country	3.5
RoA Annual % High in industry Unavailable in chosen country	2.9

All financials are in USD Million and price data in USD

Not Eligible

Mid Valuation

39.5 / 100

Technically Neutral

40.5 / 100

1Yr Price target upside is 39%

1 analysts

Check Before You Buy

Check P/E Buy Sell Zone

Sell Zone

76.0 % into P/E buy sell zone

Strong upside potential

% time spent below current P/E

Gains already realized

Oramed Pharmaceuticals, Inc Stock Price Analysis

Day Price Range -1.7% 1 Day return Unavailable in chosen country	2.3 (LTP) 2.32.4 LowHigh
Week Price Range -2.5% 1 Week return Unavailable in chosen country	2.3 (LTP) 2.32.5 LowHigh
Month Price Range 8.4% 1 Month return Unavailable in chosen country	2.3 (LTP) 22.7 LowHigh
52 Week Price Range -19.9% 1 Year return Unavailable in chosen country	2.3 (LTP) 23.1 LowHigh

View full Share Price History

Oramed Pharmaceuticals, Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Inline

Oramed Pharmaceuticals, Inc's Revenue was higher than average estimate 1 time in past 2 years

EPS forecast

QUARTER
ANNUAL

Current EPS

0.1

Avg. Estimate

-0.2

Low Estimate

-0.2

High Estimate

-0.2

Current EPS

Avg. Estimate

Miss

EPS is expected to reduce by 271.4% in FY24

Consensus Recommendation

0 ANALYST Recommendations

STRONG BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Oramed Pharmaceuticals, Inc Stock Analysis

Oramed Pharmaceuticals, Inc stock analysis with key metrics, changes, and trends.

Oramed Pharmaceuticals, Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$1.34 M	33.7%	negative	Annual Revenue fell 33.7%, in the last year to $1.34 M. Its sector's average revenue growth for the last fiscal year was 7.46%.
Annual Net Profit	$5.52 M	133.78%	positive	Annual Net Profit rose 133.78% in the last year to $5.52 M. Its sector's average net profit growth for the last fiscal year was -32.43%.
Price to Earning Ratio	21.04	-	negative	Price to Earning Ratio is 21.04, higher than its sector PE ratio of 4.23.
Stock Price	$2.33	-19.93%	negative	Stock Price fell 19.93% and underperformed its sector by 29% in the past year.
Quarterly Net profit	$19.62 M	508.91%	negative	Quarterly Net profit fell 508.91% YoY to $19.62 M. Its sector's average net profit growth YoY for the quarter was -47.3%.
Debt to Equity Ratio	0.32	-	positive	Debt to Equity Ratio of 0.32 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	3.50 %	3.5%	negative	Return on Equity(ROE) for the last financial year was 3.5%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	1.28 %	0.3%	positive	Mutual Fund Holding increased by 0.3% in the last quarter to 1.28.
Promoter Share Holding	119.63 %	10.34%	positive	Promoter Share Holding increased by 10.34% in the most recent quarter to 119.63%.
Interest Coverage Ratio	3.5	-	positive	Interest Coverage Ratio is 3.5, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).
Institutional Holding	19.18 %	1.76%	positive	Institutional Holding increased by 1.76% in the last quarter to 19.18.

VIEW LESS

Loading data..

Oramed Pharmaceuticals, Inc - Company Profile

What does Oramed Pharmaceuticals, Inc do?

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.

Oramed Pharmaceuticals, Inc Management structure

All Gross Remunerations are in USD

Mr. David Silberman

Principal Accounting Officer, Chief Financial Officer and Treasurer

2024

Gross Remuneration

Year

Mr. Avraham Gabay

Chief Financial Officer, Treasurer and Secretary

2024

Gross Remuneration

Year

Oramed Pharmaceuticals, Inc Board of directors

All Gross Remunerations are in USD

Mr. Yadin Rozov

Independent Director

2024

Gross Remuneration

Year

Mr. Yehuda Reznick

Director

2024

Gross Remuneration

Year

Oramed Pharmaceuticals, Inc Live Share Price Today, Share Analysis and Chart

25.80% Fall from 52W High

Oramed Pharmaceuticals, Inc Key Metrics

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Oramed Pharmaceuticals, Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Oramed Pharmaceuticals, Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Oramed Pharmaceuticals, Inc's Revenue was higher than average estimate 1 time in past 2 years

EPS forecast

EPS is expected to reduce by 271.4% in FY24

Consensus Recommendation

Oramed Pharmaceuticals, Inc Stock Analysis

Oramed Pharmaceuticals, Inc stock analysis with key metrics, changes, and trends.

Annual Revenue fell 33.7%, in the last year to $1.34 M. Its sector's average revenue growth for the last fiscal year was 7.46%.

Annual Net Profit rose 133.78% in the last year to $5.52 M. Its sector's average net profit growth for the last fiscal year was -32.43%.

Price to Earning Ratio is 21.04, higher than its sector PE ratio of 4.23.

Stock Price fell 19.93% and underperformed its sector by 29% in the past year.

Quarterly Net profit fell 508.91% YoY to $19.62 M. Its sector's average net profit growth YoY for the quarter was -47.3%.

Debt to Equity Ratio of 0.32 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was 3.5%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding increased by 0.3% in the last quarter to 1.28.

Promoter Share Holding increased by 10.34% in the most recent quarter to 119.63%.

Interest Coverage Ratio is 3.5, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

Institutional Holding increased by 1.76% in the last quarter to 19.18.

Oramed Pharmaceuticals, Inc - Company Profile

What does Oramed Pharmaceuticals, Inc do?

Oramed Pharmaceuticals, Inc Management structure

Mr. David Silberman

Principal Accounting Officer, Chief Financial Officer and Treasurer

Mr. Avraham Gabay

Chief Financial Officer, Treasurer and Secretary

Oramed Pharmaceuticals, Inc Board of directors

Mr. Yadin Rozov

Independent Director

Mr. Yehuda Reznick

Director

Oramed Pharmaceuticals, Inc FAQ

How is Oramed Pharmaceuticals, Inc today?

Oramed Pharmaceuticals, Inc today is trading in the red, and is down by -1.69% at 2.33.

How has Oramed Pharmaceuticals, Inc performed historically?

Oramed Pharmaceuticals, Inc is currently trading down -1.69% on an intraday basis. In the past week the stock fell -2.51%. stock has been down -1.69% in the past quarter and fell -19.93% in the past year. You can view this in the overview section.